A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
This is a Phase 1b study that incorporates dose expansion cohorts to further evaluate promising clinical or biological activity.
Refractory Solid Tumors|Melanoma
DRUG: IMO-2125
Dose Evaluation Cohorts, non-Melanoma Dose Evaluation Cohorts: Number of patients with treatment-related adverse events as assessed by CTCAE to determine the recommended Phase 2 dose (RP2D)., 51 weeks of treatment|Dose Evaluation Cohorts, non-Melanoma Dose Evaluation Cohorts: Objective response rate, Assessed every 6 weeks for duration of study participation, which is estimated to be 51 weeks|Melanoma Expansion Cohort: Objective response rate, Assessed every 9 weeks for duration of study participation, which is estimated to be 51 weeks|Melanoma Expansion Cohort: Number of patients with treatment-related adverse events as assessed by CTCAE, 51 weeks of treatment
This is a Phase 1b study that incorporates dose expansion cohorts to further evaluate promising clinical or biological activity.